A Phase 1 interventional study of Marketed paracetamol and Experimental paracetamol formulation in Pain, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-24.
Sponsored by GlaxoSmithKline · Phase 1 and Interventional
A pharmacokinetic study investigating the rate and extent of absorption of paracetamol and an adjuvant from two different paracetamol formulations.
GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Marketed paracetamol
Drug: Marketed paracetamol
Experimental formulations
Drug: Experimental paracetamol formulation
Marketed paracetamol
Experimental paracetamol formulation
Bioequivalence as measured by AUC and Cmax in fasted and semi-fed states
Time frame: baseline to 10 hours post dose
Speed of absorption in fasted and semi-fed states
Time frame: baseline to 10 hours post dose
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline